Precigen submits BLA for PRGN-2012 gene therapy targeting RRP, a rare and life-threatening condition with no cure.
Precigen Soars: Biologics License Application Submission For PRGN-2012 Targets First FDA-Approved Recurrent Respiratory Papillomatosis Treatment
